Rudy Mareel joined Polyganics as CEO in 2013. With an in-depth understanding of the global healthcare market, Rudy applies his vision and expertise to drive forward progression of Polyganics’ medical device pipeline through development all the way to commercialization.
Rudy is a seasoned executive with more than 30 years of strategic, operational, and change management experience within the healthcare industry. He has held senior leadership positions at a variety of medium and large-scale international organizations including Synthon, a privately held, speciality pharmaceutical company, where he served as CEO. Prior to this, Rudy was President for all International Business and a member of the executive leadership team at Cardinal Health, a Fortune Global 500 healthcare services company based in the US. Before Cardinal Health, Rudy was an executive Board member at Royal Numico, where he led the consolidation and launch of the Company’s global Clinical Nutrition division, serving as its first President.
Rudy established himself as a business professional at Becton Dickinson, where he assumed positions of increasing responsibility, culminating in his appointment as both Worldwide Vice President and General Manager of the company’s Immunocytometry systems based in San Jose, USA.
Rudy currently serves on the supervisory boards of several companies, including as a Lead Independent Non-Executive Director at Malin Corporation PLC, a company investing in highly innovative life sciences companies, and as Chairman of the Board for Medichem SA, NutriLeads and VitalneXt. He also acts as an advisor to investors in the global healthcare market.
Rudy holds a Bachelor of Science degree in Clinical Chemistry from the Industrial Institute of Technology, Ghent (Belgium).